Abstract
Purpose: To create a unified system of accelerated clinical trials of new drugs and regimens for breast cancer (BC).
Materials and methods: The study included 1214 patients with BC of different stages (cT1N1, cT2N1-2, cT2-3N0-2, cT2-3N0-1, cT4N0M0). According to trepan biopsy data and immunohistochemical examination (IHC) expression of ER, PR, HER2, and Ki67 was determined. The expression TUBBßIII, TOP2a, analyzes on the BRCA1/2 mutation was studied. The clinical response to neoadjuvant treatment was determined using the physical method, ultrasonography-elas-tography, mammography, contrast magnetic resonance imaging (MRI) and single-photon emission computer mammotography (SPECT-CT).
Results: The correlation index of complete responses (cCR) and total pathomorphological responses (pCR) according to MRI was 0.80, according to ultrasound - 0.61, mammography - 0.60, palpation - 0.57. The low level of amplification of the TUBßIII mRNA gene with a high level of amplification of the TOP2-a gene is a predictor of the achievement of pCR. The inclusion of a neoadjuvant treatment of triply-negative BC carboplatin in addition to paclitaxel or eribulin increases the frequency of reaching pCR (ypT0/is(yp)N0) from 20.3% to 47%.
References
Давыдов М.И. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. - Москва: Издательская группа РОНЦ, 2014. - 226 с.
Семиглазов В.Ф., Семиглазов В.В. Рак молочной железы: биология, местное и системное лечение. - Москва, СИМК, 2014. - 352 с.
Семиглазов В.Ф., Криворотько П.В., Семиглазова Т.Ю. и др. Практические рекомендации по лечению рака молочной железы. - Мегаполис, М., 2017. - 168 с.
Семиглазов В.Ф., Криворотько П.В., Семиглазов В.В., Дашян Г.А., Палтуев РМ. Рекомендации для врачей по ведению пациентов с раком молочной железы. Специализированное издание, предназначенное для медицинских и фармацевтических работников. - Москва, 2017.
Семиглазов В.Ф. Лечение рака молочной железы: клинико-биологическое обоснование / Под ред. проф. В.Ф. Семиглазова, д.м.н. В.В. Семиглазова. - Москва: СИМК, 2017. - 272 с.
Goldhirsch A., Winer E.P., Coates A.S., et al. Personalizing the treatment of women with early breast cancer: highlights of the st Gallen International expert Consensus on the Primary Therapy of early Breast Cancer 2013 // Ann oncol. - 2013. - Vol. 24. - P 2206-2223.
Chia S.K. Neoadjuvant and Adjuvant therapy for HER2 Positive Disease // Clin. oncol. - 2015. - Vol. 35. - P 41-48.
Vas-Luis I., Ottesen R.A., Hughes M.E. et al. outcomes by tumor subtype and treatment pattern in women with small node negative breast cancer: a multi-institutional study // J. Clin. oncol. - 2014. - Vol. 32. - P. 2142-2150.
Bianchini G., Pusztai L., Pienkowski t. et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the Neosphere trial // Ann. oncol. - 2015. - Vol. 26 (12). - P. 2429-2436.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018